Skip to main content
SpringerLink
Log in

A polymorphism at miRNA-122-binding site in the IL-1α 3′UTR is associated with risk of epithelial ovarian cancer

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

We aimed to investigate the association between rs3783553 polymorphism and susceptibility to epithelial ovarian cancer in a Chinese population and discussed the risk factors associated with survival time. In a case–control study, 301 patients diagnosed with epithelial ovarian cancer and 240 healthy controls were genotyped for rs3783553 polymorphism. Survival time of ovarian cancer patients was explored by Kaplan–Meier analysis and Cox proportional hazards modeling. The distributions of genotype and allele frequencies were significantly different between cases and controls. The variant homozygote (ins/ins) was associated with a significantly reduced risk of ovarian cancer. The patients with del/ins polymorphism seemed to be diagnosed “earlier” (FIGO stage I–II) and be more likely to achieve optimal cytoreductive surgery. Advanced FIGO stage (stages III–IV) and non-optimal cytoreductive surgery (residual tumor <1 cm) were poor prognostic factors in the univariate analysis. However, optimal cytoreductive surgery was found to be the only independent significant prognostic factor. This study suggests that rs3783553 polymorphism may be involved in the susceptibility to epithelial ovarian cancer. It may also be related with the tumor stage and the ability to achieve optimal tumor surgery, while the latter predicts the clinical outcomes for patients as the only independent prognostic factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166

    Article  PubMed  Google Scholar 

  2. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338. doi:10.1016/S0140-6736(09)61157-0

    Article  CAS  PubMed  Google Scholar 

  3. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039–2045. doi:10.1200/JCO.2012.42.0505

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK (2012) Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci 1271:58–67. doi:10.1111/j.1749-6632.2012.06734.x

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Xing D, Orsulic S (2005) A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA 102(19):6936–6941. doi:10.1073/pnas.0502256102

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L (2013) Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 130(3):674–681. doi:10.1016/j.ygyno.2013.06.029

    Article  PubMed  Google Scholar 

  7. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466(7308):835–840. doi:10.1038/nature09267

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, Wu M, Shen SH (2007) Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucl Acids Res 35(13):4535–4541. doi:10.1093/nar/gkm480

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 105(20):7269–7274. doi:10.1073/pnas.0802682105

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, L’Abbe D, Yu Z, Shen SH (2008) Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 29(9):1710–1716. doi:10.1093/carcin/bgn073

    Article  CAS  PubMed  Google Scholar 

  11. Nicklin MJ, Weith A, Duff GW (1994) A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 19(2):382–384. doi:10.1006/geno.1994.1076

    Article  CAS  PubMed  Google Scholar 

  12. Mustea A, Sehouli J, Konsgen D, Stengel D, Sofroni D, Lichtenegger W (2003) Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. Anticancer Res 23(2A):1099–1102

    CAS  PubMed  Google Scholar 

  13. Sehouli J, Mustea A, Koensgen D, Lichtenegger W (2003) Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer. Cancer Epidemiol Biomark Prev 12(11 Pt 1):1205–1208

    CAS  Google Scholar 

  14. Lee KM, Park SK, Hamajima N, Tajima K, Choi JY, Noh DY, Ahn SH, Yoo KY, Hirvonen A, Kang D (2006) Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women. Breast Cancer Res Treat 96(2):197–202. doi:10.1007/s10549-005-9079-6

    Article  CAS  PubMed  Google Scholar 

  15. Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, Landi D, Landi S, Zhou Y, Liu H (2009) An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1α 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 30(12):2064–2069. doi:10.1093/carcin/bgp283

    Article  CAS  PubMed  Google Scholar 

  16. Yang ZH, Dai Q, Zhong L, Zhang X, Guo QX, Li SN (2011) Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma. Mol Carcinog 50(3):208–214. doi:10.1002/mc.20706

    Article  CAS  PubMed  Google Scholar 

  17. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor–host interactions. Cancer Metastasis Rev 25(3):387–408. doi:10.1007/s10555-006-9004-4

    Article  CAS  PubMed  Google Scholar 

  18. Gubbay O, Guo W, Rae MT, Niven D, Langdon SP, Hillier SG (2005) Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas. Br J Cancer 92(10):1927–1933. doi:10.1038/sj.bjc.6602568

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Papacleovoulou G, Critchley HO, Hillier SG, Mason JI (2011) IL1alpha and IL4 signalling in human ovarian surface epithelial cells. J Endocrinol 211(3):273–283. doi:10.1530/JOE-11-0081

    Article  CAS  PubMed  Google Scholar 

  20. Rae MT, Niven D, Ross A, Forster T, Lathe R, Critchley HO, Ghazal P, Hillier SG (2004) Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1α determined by microarray analysis. J Endocrinol 183(1):19–28. doi:10.1677/joe.1.05754

    Article  CAS  PubMed  Google Scholar 

  21. Keita M, Bessette P, Pelmus M, Ainmelk Y, Aris A (2010) Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. J Ovarian Res 3:3. doi:10.1186/1757-2215-3-3

    Article  PubMed Central  PubMed  Google Scholar 

  22. Frede S, Freitag P, Otto T, Heilmaier C, Fandrey J (2005) The proinflammatory cytokine interleukin 1β and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation. Cancer Res 65(11):4690–4697. doi:10.1158/0008-5472.CAN-04-3877

    Article  CAS  PubMed  Google Scholar 

  23. Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Konsgen D, Sun P, Nurnberg P, Lichtenegger W, Sehouli J (2007) Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients. Gynecol Oncol 104(3):680–685. doi:10.1016/j.ygyno.2006.10.014

    Article  PubMed  Google Scholar 

  24. Santtila S, Savinainen K, Hurme M (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 47(3):195–198

    Article  CAS  PubMed  Google Scholar 

  25. Zeng XF, Li J, Li SB (2013) A functional polymorphism in IL-1A gene is associated with a reduced risk of gastric cancer. Tumour Biol. doi:10.1007/s13277-013-1034-2

    PubMed Central  Google Scholar 

  26. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101(5 Pt 1):885–891

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by The National Natural Science Foundation Grants of China (No. 81172494).

Conflict of interest

The authors have no conflict of interest.

Ethical standard

This study was performed with the approval of the Medical Ethical Review Committee of West China Second University Hospital of Sichuan University, and informed consent was obtained from all of the participants.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, No. 20, 3rd Section, South Renmin Road, Chengdu, 610041, Sichuan, China

    Zhu Zhang, Bin Zhou, Qianqian Gao, Yuke Wu, Yaping Song, Lin Zhang & Mingrong Xi

  2. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China

    Zhu Zhang & Mingrong Xi

  3. Laboratory of Molecular Translational Medicine, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

    Bin Zhou, Yaping Song & Lin Zhang

  4. Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China

    Kui Zhang & Yan Pu

Authors
  1. Zhu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qianqian Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuke Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan Pu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yaping Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mingrong Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lin Zhang or Mingrong Xi.

Additional information

Zhu Zhang, Bin Zhou, Qianqian Gao, Yuke Wu, Yaping Song, Lin Zhang and Mingrong Xi have contributed equally to the work and each is considered first author.

Zhu Zhang and Bin Zhou have contributed equally to the work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Z., Zhou, B., Gao, Q. et al. A polymorphism at miRNA-122-binding site in the IL-1α 3′UTR is associated with risk of epithelial ovarian cancer. Familial Cancer 13, 595–601 (2014). https://doi.org/10.1007/s10689-014-9739-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-014-9739-y

Keywords

Search

Navigation